MSH2 Gene clinical trials
20 active trials name this biomarker in their eligibility criteria. Describe your situation to see which ones you may be eligible for.
- Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
- The Cancer of the Pancreas Screening-5 CAPS5)Study
- A Study of Magnetic Resonance Imaging of the Pancreas for Cancer Screening
- Targeted Early Detection Program in Men at High Genetic Risk for Prostate Cancer
- FITting Non-invasive Tests in Lynch Syndrome Surveillance
- Lynch Syndrome Integrative Epidemiology and Genetics
- Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts
- Collecting Blood and Stool Samples to Detect Colorectal Cancer or Advanced Neoplasia in Lynch Syndrome Patients
- Prostate Cancer Genetic Risk Evaluation and Screening Study
- Pancreatic Cancer Screening for At-risk Individuals
- Precision-Based Genomics in Prostate Cancer
- Men at High Genetic Risk for Prostate Cancer
- A Pancreatic Cancer Screening Study in Hereditary High Risk Individuals
- Lynch Syndrome X-Talk of Enteral Mucosa With Immune System
- Pancreatic Cancer Early Detection Consortium
- IGNITE-TX Phase III: (Identifying Individuals for Genetic Testing & Treatment) Intervention
- ACT-GEN (Adherence And Care Tracking In GENetic Cancer Syndromes)
- A Web-Based Program (Kindred) to Improve the Understanding of Genetic Cancer Risk and Cancer Genetic Testing in African American Families
- Prospective Familial Registry for Pancreas Research
- Patient Centered Clinical Decision Support for Hereditary Cancer Syndromes
Guides for people searching for a trial
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that name “MSH2 Gene” in their eligibility criteria, at any level. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.